Industries · Immuno-oncology
OMICS4 runs the multi-omics profiling behind tumour microenvironment studies: bulk and single-cell RNA-seq, targeted quantification and, through our partnership with MIPP, plasma protein panels built for immuno-oncology.
Platforms used in this field
Overview
OMICS4 runs the laboratory work behind immuno-oncology studies. Tumor and immune compartments are extracted, sequenced and quality-controlled in our own laboratories, and returned as primary data your team can analyse directly or hand to GenXMap.
Platforms
RNA and DNA recovered from difficult tumour material.
Sequencing and targeted quantification on the same material.
Plasma protein measurement alongside the sequencing layers.
FFPE blocks and slides, fresh-frozen tumour tissue, core biopsies, PBMC, whole blood, plasma and dissociated cell suspensions. Input amounts, RIN thresholds and DNA quality criteria are published per sample type. Archival and low-input material is handled routinely: if your material sits below the published thresholds, say so in the quote request and we will tell you what is feasible before you ship.
A QC report for every sample. Demultiplexed FASTQ with run-level QC metrics for the sequencing services. Result tables for PCR and protein work.
Alignment, quantification, integration, biomarker discovery and modelling are not part of a platform booking. They are run by GenXMap's R&D team, as the Immune Response Signature Package, a programme designed for your industry rather than a line on a quote. Ask for it in the quote request and both are scoped together.
Immune Response Signature Package at GenXMapHave a project in this space?